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Background: Identification and treatment of latent tuberculosis infec-
tion (LTBI) is a critical component of the United States national plan for 
tuberculosis disease (TB) elimination. However, estimating LTBI preva-
lence has been challenging. In this study, we present a back-calculation 
model based on reported active TB disease to estimate the prevalence 
of LTBI within the United States (U.S.), California, and five counties in 
California with the highest burden of TB.
methods: Our model incorporates annual TB cases (1993 to 2016) re-
ported to CDC and annual mortality-adjusted reactivation risks for 85 
years following infection to “back-calculate” LTBI prevalence. We used 
Markov Chain Monte Carlo to calibrate an exponential decay curve fit to 
surveillance data to estimate reactivation risks, then adjusted the reac-
tivation risks for all-cause mortality risks. Calculations were done using 
a back-calculation package in R software after accounting for the long 
lag between LTBI and active disease, and general all-cause mortality as 
a competing risk. We produced uncertainty limits (UL) using lower and 
upper bounds for reactivation risks and the LTBI prevalence.
results: The mortality-adjusted reactivation risk in the first year follow-
ing infection was 1.42% (UL 1.40 to 1.43), and the lifetime cumulative risk 
for 85 years was 7.12% (UL 4.70 to 9.54). The back-calculation estimates 
suggest that 2.36% (UL 1.61 to 4.09) of U.S. population in 2016 were living 
with LTBI (corresponds to 7.65 million (UL 5.22 to 13.25)]. Estimated LTBI 
prevalence in 2016 was 4.07% (UL 2.71 to 7.23) in California, 5.29% (UL 
3.80 to 8.18) in Alameda County, 5.51% (UL 3.50 to 10.23) in Los Angeles 
County, 4.13% (UL 2.72 to 7.38) in Orange County, 4.79% (UL 3.22 to 8.28) 
in San Diego County, and 5.60% (UL 3.97 to 8.81) in Santa Clara County.
conclusions: Our LTBI prevalence estimates are similar with previous 
estimates from the 2011-2012 National Health and Nutrition Examination 
Survey (NHANES) for the U.S. (2.1%) when TST & IGRA combined posi-
tivity was used to define the LTBI infection, and in range with NHANES 
estimates extrapolated to state and county demographics for California 
(5.99%), and the five counties (5.18%-8.20%). Our model can be used at 
national, state, and county levels to estimate LTBI. 
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secondary prevention of cervical cancer into HIV care 
in Kenya: A mathematical modelling study
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Imperial College, London, Department of Infectious Disease Epidemiology, 
London, United Kingdom
Background: Practice guidelines in Kenya recommend secondary pre-
vention of cervical cancer (CC) through a ‘screen-and-treat’ approach for 
pre-cancerous lesions of the cervix. The Ministry of Health recognises 
HIV care as one of the most effective platforms for integrating such ser-
vices. However, CC screening coverage remains low, at an estimated 
3.2% country-wide. We aim to quantify the impact of fully implement-
ing guideline recommendations on CC incidence amongst HIV-positive 
women in care (HIV-WiC).
methods: We developed an individual-based multi-disease model of 
the HIV and HPV epidemics in Kenya. The model was parameterised 
with and fitted to national and regional surveillance and epidemiological 
data (Figure 1A). We compared projections of the status quo levels 
of HPV screening to a scenario of 100% coverage of HIV-WiC with 
visual inspection which acetic acid (VIA) and, if indicated, treatment 
of pre-cancerous lesions (cervical intraepithelial neoplasia 1 to 3) with 
cryotherapy (Cry). We assumed VIA sensitivity to range from 48% to 76% 
and Cry success rates of 87.5% based on literature. Screening intervals 
were 6-monthly, for the first year, followed by annual, as per national 
guidelines.
results: Our model predicts a baseline of 18,600 CC cases (18,078-
19,123) between 2018 and 2035 amongst HIV-WiC, with an incidence of 
215.35 (208.96-221.76) per 100,000 person-years (py). Integrating screen-
and-treat services with VIA/Cry in this population could avert 72% to 
74% of cases (13,480-13,700) and reduce CC incidence to 56 to 58 per 
100,000py (48-69), depending on VIA sensitivity (Figure 1). Widespread 
availability of specialised services for the treatment of carcinoma in situ 
could further avert up to 20% of pre-invasive cancer cases, potentially 
driving CC incidence down to 38 per 100,000py.
conclusions: In the absence of effective secondary prevention 
programs, HIV-WiC are at an increased risk of CC than HIV-negative 
populations. Our modelled projections are in agreement with this. 
Despite variability in VIA performance, scaling-up VIA/Cry in HIV-WiC in 
Kenya could forestall a large proportion of HPV-related morbidity.
[Figure 1 - Modelled cervical cancer incidence rate in HIV-WiC from 2018 
to 2035, with varying levels of VIA sensitivity from pre-cancerous lesions 
(ce]
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Background: Non-communicable diseases (NCDs) are a significant and 
growing source of morbidity and mortality among HIV positive people in 
sub-Saharan Africa. In Kenya, pilot integrated care programs providing 
services for both HIV and chronic NCDs such as hypertension and diabe-
tes are emerging in some counties, but there is little information about 
the growth of overlapping conditions at the clinical and population level 
to provide a basis to assess healthcare needs. The research described 
within this abstract generates foundational knowledge of potential de-
mand for integrated care in two ways; by assessing development of hy-
pertension among a longitudinal clinical cohort of people living with HIV, 
and modeling the dual burden of NCD and HIV at the population level.
